Interní Med. 2008; 10(11): 511-516

Pharmacotherapy of diabetic retinopathy - idle wishes or reality?

doc. MUDr. Tomáš Sosna CSc1,2
1 Oční ambulance kliniky diabetologie a experimentální terapie IKEM, Praha
2 Oční oddělení, Fakultní Thomayerova nemocnice, Praha

Diabetic retinopathy (DR) is one of the most frequent causes of decrease of vision in developed countries. It is known that the most important is prevention that lays on optimal control of diabetes, but also other risk factors. Laser therapy, in spite of being „evidence based“, is a strategy essentially empiric and destructive and principles of therapy effects are not well understood. Pharmacotherapy of DR tries to be based on well known facts in pathophysiology and histopathology of the disease and to influence the process selectively. The article discusses individual groups of medications and their influence of diabetic retinopathy.

Keywords: Key words: diabetic retinopathy, pathophysiology, pharmacotherapy.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sosna T. Pharmacotherapy of diabetic retinopathy - idle wishes or reality? Interní Med. 2008;10(11):511-516.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adamis AP, Miller JW, Bernal MT, et al. Elevated vascular permeability factor, vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450. Go to original source... Go to PubMed...
    2. Barnes, AJ, Kohner E M, Johnston DG, Alberti KGM. Severe retinopathy and mild carbohydrate intolerance: possible role of insulin deficiency and elevated circulating growth hormone. Lancet 1985; 1/8444: 1465-1468. Go to original source... Go to PubMed...
    3. Cohen RA, Hennekens CH, Christen WG, Krolewski A, Nathan DM, Peterson MJ, LaMotte F, Manson JE. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999; Jul 107: 145-151. Go to original source... Go to PubMed...
    4. Češka R. Ovlivnění diabetické retinopatie účinky fenofibrátu - studie FIELD. Farmakoterapie 2008; 3: 271-275.
    5. Donnelly R, Iris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research British Journal of Ophthalmology 2004; 88: 145-151. Go to original source... Go to PubMed...
    6. Forrester JV, Shafiee AF, Schroder S, Knott R, McIntosh L. The role of growth factors in proliferative diabetic retinopathy. Eye 1993; 7: 276-287. Go to original source... Go to PubMed...
    7. Frank RN. The aldose reductase controversery. Diabetes 1994; 43: 169-172. Go to original source... Go to PubMed...
    8. Group STR. A randomised trial of sorbinil an aldoso reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990; 108: 1234-1244. Go to original source... Go to PubMed...
    9. Hollay E, Piťhová P, Kvapil M. Diabetes mellitus a hypertenze. Interní Med. 2006; 5: 219-222.
    10. Chantelau E. Evidence that upregulation of serum IGF - 1 concentration can trigger acceleration of diabetic retinopathy. Br. J. Ophthalmol.1996; 82: 725-730. Go to original source... Go to PubMed...
    11. Kador PF, Aiello LP, Porta M, Wilkinson CP. Symposium: Future therapies for diabetic microvascular disease: the eye as a model. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13-17, 2003; New Orleans, Louisiana.
    12. Ryan SJ. Retina, Vol. 2., 3th edition. St. Louis Mosby 2001.
    13. Szabo C, Obrosova I, Hammes HP, Miyata T. Oxidative stress and downstream mechanisms in microvascular complications. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13-17, 2003; New Orleans, Louisiana.
    14. Yasuda Y, Clermont A, Takahara N, Takahaski J, King G. Characterization of retinal abnormalities in vascular targeted overexpression of PKC beta2 isoform transgenic mice. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13-17, 2003; New Orleans, Louisiana. Abstract 879-P.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.